Assay for the identification of cytochrome (CYP) 2D6 gene mutations
based on polymerase chain reaction (PCR) and reverse-hybridization.
The cytochrome P450 2D6 (CYP2D6) is a liver enzyme involved in the metabolism of more than 25% of the most frequently used drugs in the clinical field. Variants of the highly polymorphic CYP2D6 gene are associated with altered enzymatic function, ranging from a complete lack of activity to an ultrarapid metabolization of drugs.
This altered CYP2D6 activity causes an inter- individual variability in drug-response. Patients with a defective or over-active CYP2D6 enzyme are either at risk to develop severe adverse events or do not reach the therapeutic window for effective treatment with a specific drug. Hence, pharmacogenetic guidelines recommend a CYP2D6-related dose-adjustment for numerous drugs.
The ViennaLab PGX-CYP2D6 XL StripAssay® in combination with the CYP2D6 RealFast CNV Assay identifies patients with an altered CYP2D6 enzyme function. Comprehensive CYP2D6 genotyping optimizes the choice of medication and/or the adjustment of drug dosage and consequently reduces the risk of adverse events or lowered treatment efficacy.
- Comprehensive CYP2D6 analysis
- Cost-efficient technologies
- Rapid and simple workflow
- PGX-CYP2D6 XL StripAssay® for detection of the most prevalent CYP2D6 alleles
- CYP2D6 RealFastTM CNV Assay for identification of CYP2D6 deletions or duplications